

Blood pressure in relation to frailty in older adults: a population-based study

Daniela Anker, MSc^a, Prof Brigitte Santos-Eggimann, MD MPH DrPH^b, Prof Marcel Zwahlen, PhD^c, Prof Valérie Santschi, PharmD, PhD^d, Prof Nicolas Rodondi, MD^{a,e}, Prof Christina Wolfson, PhD^f, Prof Arnaud Chiolerio, MD PhD^{a,f,g}

^aInstitute of Primary Health Care (BIHAM), University of Bern, Switzerland; ^bCenter for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland; ^cInstitute of Social and Preventive Medicine, University of Bern, Switzerland; ^dLa Source, School of nursing sciences, HES-SO University of Applied Sciences and Arts Western Switzerland, Switzerland; ^eDepartment of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; ^fDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Canada; ^gPopulation Health Laboratory, Department of Community Health, University of Fribourg, Switzerland

Corresponding author: Daniela Anker MSc, Institute of Primary Health Care (BIHAM), University of Bern, Switzerland; Tel: +41 31 631 58 68; e-mail: daniela.anker@biham.unibe.ch

Keywords: Frailty, Hypertension in the Elderly, Population-Based, Epidemiology, Observational

Running title: Blood pressure and frailty in older adults

Statement of Financial Disclosure: No conflict of interest to disclose. The Lc65+ study has been supported by University of Lausanne Hospital Centre; University of Lausanne Department of Ambulatory Care and Community Medicine; Canton de Vaud Department of Public Health; City of Lausanne; Loterie Romande [research grants 2006-2008 and 2018-2019]; Lausanne University Faculty of Biology and Medicine [multidisciplinary research grant 2006]; Swiss National Foundation for Scientific Research [grant 3247B0-120795/1]; and Fondation Médecine Sociale et Préventive, Lausanne. The sponsors had no role in the design, execution, analysis and interpretation of data, or writing of the study.

Previous presentation: parts of these findings were presented as a poster at the Swiss Public Health conference 2018 in Neuchâtel, Switzerland, on 7-8.11.2018.

Word count: 3535 (manuscript only),

Number of tables: 4

Number of figures: 2

Number of supplementary digital content files: 3

Abstract

In frail older adults, low blood pressure (BP) might be associated with worse health outcomes and hypertension management in this population is highly debated. Using data from a population-based study of older adults, we assessed the association between frailty and BP. We used data collected between 2014 and 2016 from 3157 participants aged between 67 and 80 years in the Lausanne cohort Lc65+. BP was measured three times at one visit and frailty status was assessed based on Fried's phenotype model. We analyzed the cross-sectional association between BP and frailty by computing mean systolic and diastolic BP stratified by sex, age, and frailty and by fitting regression models. The average age of the participants was 73.3 (standard deviation (SD): 4.1) years and 59.1% were women. 34.1% were pre-frail, and 3.3% were frail. Mean BP was 135.1/76.3 mmHg (SD 18.5/11.0). Age- and sex-adjusted systolic BP was on average lower by 2.8 mmHg (95% confidence interval (CI): 1.4 to 4.2) and 6.7 mmHg (95% CI: 3.2 to 10.3) among pre-frail and frail compared to non-frail participants. Similar differences in mean diastolic BP across frailty status were found. Upon adjustment for antihypertensive treatment, the associations between frailty status and BP did not change substantially. Frail individuals had a substantially lower BP compared with non-frail older adults. Because low BP could be detrimental among frail older patients, our findings raise questions about hypertension management in this population and stress the need for additional evidence.

Introduction

Lowering blood pressure (BP) is known to be beneficial in middle-aged adults, but recent research suggests that the benefit is questionable in older adults depending on their health status.^{1,2} Numerous trials have shown that lowering BP decreases the risk of cardiovascular disease (CVD) and mortality in middle-aged adults.³⁻⁶ In older adults, however, the evidence is scarce. While two trials including participants aged 75 or 80 years and over have shown that lowering BP reduced all-cause mortality and cardiovascular mortality^{7,8}, several cohort studies have shown that older individuals with relatively low BP had higher mortality rates and worse physical and cognitive abilities compared to older individuals with higher BP.⁹⁻¹¹ Hence, how to manage high BP among older adults remains highly debated, including in recent major guidelines.^{4,5}

In older adults, frailty may modify the relationship between BP and health outcomes.^{1,12,13} Frailty is a multidimensional geriatric syndrome characterized by increased vulnerability and loss of adaptability to stress.¹⁴⁻¹⁶ It is associated with an increased risk of falls, delirium, disability and mortality.^{15,17} In a cohort study, van Hateren et al. showed that frail participants with high BP had lower mortality rates compared to frail participants with low BP.¹³ In another cohort study, Odden et al. showed that fast walking participants – considered as non-frail – with high BP had higher cardiovascular mortality rates compared to those with low BP; among slow walking participants – considered as frail – there was no difference in cardiovascular mortality rates across levels of BP.¹² This suggests that a relatively low BP might be not beneficial and may even be detrimental in frail older adults.

At the population level, the relationship between frailty, BP, and antihypertensive treatment remains poorly described.¹ Using data from a population-based study¹⁶, we assessed the cross-sectional association between BP and frailty in individuals aged between 67 and 80 years.

Methods

Population

We analyzed data from participants in the Lausanne cohort Lc65+, a population-based study of community-dwelling older adults. The Lc65+ was designed primarily to investigate the determinants, evolution, and outcomes of frailty.¹⁶ A total of 4731 randomly selected community-dwelling residents of the city of Lausanne, Switzerland, were recruited at age 65 to 70 years in three waves at three different time points: sample 1 (C1) in 2004, sample 2 (C2) in 2009 and sample 3 (C3) in 2014.¹⁸ Follow up is ongoing. Individuals were excluded if they were living in an institution or if they were unable to respond by themselves to questionnaires due to advanced dementia.

Data collection

Data was collected by means of self-administered mailed questionnaires, in-person interviews, and anthropometric measurements. Performance tests were conducted by trained research assistants at the study center, and, in some cases, at participants' homes. For this analysis, we used data collected at baseline and at the most recent data collection for the 3 samples. The most recent data collection for the samples C1, C2, and C3 took place in 2014, 2016, and 2015, respectively. Details of time points of data collection for each variable included in the analyses are given in **Table S1** in the supplementary digital content files.

Blood pressure measurement and definition of hypertension

BP was measured following a standardized protocol kept identical across years in the three samples. Measures were made at the study center by trained medical research assistants using a clinically validated oscillometric automated device (Omron® 907 (HEM-907-E) digital automatic blood pressure monitor).^{19,20} In case of heart rhythm abnormalities, BP was measured using the auscultatory method with an Erkameter 3000® mercury tensiometer and a Duophon® or a Littmann® stethoscope. After 10 to 20 minutes of rest in a sitting position, BP was measured three times at 5 to 10 minutes intervals with a cuff size adapted to the participant's arm circumference. Three cuff sizes were available: 17-22cm (HEM-CS19) for arm circumference less than 22 cm, 22-32 cm (HEM-CR19) for arm circumference between 22 and 32 cm, and 32-42 cm (HEM-CL19) for arm circumference 33 cm and larger. BP was measured on the left arm. During the measurement, the participant was relaxed, sitting comfortably with his or her back supported, left arm resting on a support at level of the heart, and with the palm of the hand up.¹⁶

Participants were classified as hypertensive (self-reported) if they answered “yes” to following questions: “Has a doctor ever told you that you have too high a blood pressure (hypertension)” or “Are you currently taking any medication to lower your blood pressure (hypertension) at least once a week?”. We have also explored further definitions of hypertension, respectively elevated BP by computing the number of participants with $BP \geq 140/90$ mmHg and the number of participants with $BP \geq 140/90$ mmHg OR self-reported antihypertensive use.

Frailty definition and measurement

Frailty was assessed according to Fried's phenotype model following a standardized procedure kept identical across years in the three samples.^{16,21} Fried's phenotype model is based on five characteristics, that is, shrinking, exhaustion, weakness, slowness, and low activity. Shrinking was identified if the participant reported any unintentional weight loss in the prior year. Exhaustion was identified if a participant answered “a lot”, as compared to “not at all” or “a little”, to the question “did you have feelings of generalized weakness, weariness, lack of energy in the last four weeks?”. Weakness was identified if the highest value of three measures of grip strength was considered as low. Low grip strength was identified when participants' measures were below certain sex- and body mass index-specific cut-off values, as defined in the Cardiovascular Health study.²¹ Grip strength was measured on the right hand with a DHD-3 Digital Hand Dynamometer SAEHAN® Baseline® hydraulic dynamometer.²² Walking speed was measured at the study center and slowness was identified if the participant had a low walking speed over 20 meters. Low walking speed was identified when participants' measures were below certain sex- and height-specific cut-off values, as defined in the Cardiovascular Health study.²¹ In some cases slowness was imputed based on the judgement of the research assistant following a decision algorithm. Briefly, the decision algorithm included 3 criteria: the use of walking aids, the opinion of a medical assistant on whether the participant's gait speed was slowed down, difficult or impossible, and the participant's performance in getting up from a chair. Low activity was identified if the participant reported less than 20 minutes of sport activity once a week and less than 30 cumulated minutes of walking per day 3 times a week and avoiding to climb stairs or carrying light loads in daily activities. Participants were classified as non-frail, pre-frail, or frail if they had none, one to two, or three to five of these characteristics, respectively.¹⁶

Assessment of other characteristics

Hypercholesterolemia was defined if participants reported taking cholesterol-lowering medication or having been diagnosed with high cholesterol by a physician. Diabetes was defined if participants reported taking medication for diabetes or having been diagnosed with diabetes by a physician. History of CVD was defined if participants reported having been diagnosed with coronary heart disease, stroke, heart insufficiency, cardiomyopathy, heart valve disease, or other cardiopathy, or if they reported taking medication for the heart. Participants were interviewed about the presence of the following chronic diseases: arthrosis, Alzheimer's disease, asthma, cancer, heart failure, coronary heart disease, chronic pulmonary disease, Parkinson's disease, ulcer, HIV, osteoporosis, hypertension, hypercholesterolemia, and diabetes. Functional status was assessed using Katz' basic activities of daily living (BADL) and Lawton's instrumental activities of daily living (IADL).^{23,24} To assess BADL, participants were asked if they had "no difficulties", "difficulties but not receiving help", or "difficulties and receiving help" with following activities: taking a bath or a shower, eating, getting in and out of bed or sofa, dressing, and using the toilet. To assess IADL, participants were asked if they had "no difficulties", "difficulties but not receiving help", or "difficulties and receiving help" with following activities: doing light housework, cooking, making phone calls, taking medication, shopping, and taking care of finances. Polypharmacy was defined if participants reported taking five types of medications at least once a week.² Financial difficulties were defined if participants reported having had financial difficulties in the past 12 months, having trouble making ends meet, receiving means-tested subsidies for health insurance or receiving complementary financial support in addition to old-age pension.

Statistical analyses

We used data from all the participants of the Lc65+ who were still enrolled in the study and who participated at the most recent data collection. To assess the cross-sectional association between BP and frailty, we restricted the analytical sample to the set of participants with complete data for all variables that we selected for our final regression models. First, we computed the number of participants (%) with hypertension and antihypertensive treatment use, stratified by sex, age and frailty. Second, we analyzed the association between BP and frailty by computing mean (SD) systolic BP and mean (SD) diastolic BP stratified by sex, age and frailty. Third, we analyzed the association between BP and frailty by fitting multivariable linear regression models. For systolic BP and diastolic BP, separately, we fitted similar sets of three hierarchical linear regression models. In model 1, BP was regressed on frailty status (dummy variable), adjusted for age and sex. In model 2, estimates were additionally adjusted for socio-economic characteristics (education, Swiss citizenship, financial difficulties, living alone), CVD risk factors (hypercholesterolemia, diabetes, history of CVD, smoking), and body mass index (BMI). In model 3, estimates were additionally adjusted for antihypertensive medication use. We used Stata 14® (Stata Corp, College Station, TX) for all analyses.

Results

Figure 1 is a flow chart with the number of participants recruited in each sample (C1, C2, and C3), the number and reasons for dropouts between recruitment and most recent data collection, and the number of participants not considered in the analyses due to missing data. Briefly, out of the 4731 individuals initially recruited in 2004, 2009 and 2014, 3651 individuals participated in the most recent data collection and 3157 had complete data and were included in our analyses (see **Table S2** in the supplementary digital content files for detailed flow charts separately for each of the three samples). There was no major

difference in main baseline characteristics between participants with and without missing data (see **Table S3** in the supplementary digital content files). In the analytical sample, slowness was imputed for 60 participants (1.9%). The main reason was a follow-up done outside of the study center, where a walking test could not be performed.

Table 1 summarizes baseline characteristics of the participants. Some 2157 were women (59.1%) and 1494 were men (40.9%). Mean age of participants was 73.3 (SD: 4.1) years. Some 2226 (61.0%) were non-frail, 1243 (34.1%) pre-frail, and 121 (3.3%) frail. Mean BP was 135.1/76.3 mmHg (SD 18.5/11.0). Some 1867 (51.1%) reported diagnosed hypertension and 1601 (43.9%) reported that they were using antihypertensive medication.

Table 2 shows that the proportion of participants with hypertension tended to be higher in men compared to women and increased with age. The proportion of hypertension and use of antihypertensive treatment increased across categories of frailty status.

Table 3 shows that mean systolic BP and mean diastolic BP was lower in women than in men. While mean systolic BP tended to be higher in higher age categories, mean diastolic BP tended to be lower in higher age categories. Mean systolic BP and mean diastolic BP were lowest in frail participants and highest in non-frail participants. These differences in BP by frailty status were observed consistently across all sex- and age-categories of participants.

Table 4 shows that, compared to non-frail participants, mean age- and sex-adjusted systolic BP was lower by 2.7 mmHg (95% confidence interval (CI): 1.4 to 4.1) and 6.7 mmHg (95% CI: 3.2 to 10.3) among pre-frail and frail participants, respectively. Compared to non-frail participants, mean age- and sex-adjusted diastolic BP was lower by 1.9 mmHg (95% CI: 1.1 to 2.8) and 4.9 mmHg (95% CI: 2.8 to 7.0) in pre-frail and frail participants, respectively (model 1). Upon adjustment for socio-economic characteristics, CVD risk factors, and BMI, BP remained lower among pre-frail and frail participants compared to non-frail (model 2). With additional adjustment for antihypertensive treatment (model 3), the difference in BP between non-frail, pre-frail, and frail participants remained similar.

Sensitivity analyses with age included as a simple or quadratic continuous variable did not modify our findings. In further sensitivity analyses, we have tested for interactions between frailty and sex, age categories, hypercholesterolemia, diabetes, history of cardiovascular disease and smoking, respectively. None of these terms was statistically significantly associated with BP. Further, including these terms in the regression models did not modify our findings.

Discussion

Using data from a population-based study of older adults, we found that BP was lower among pre-frail and even lower among frail compared to non-frail individuals. This difference in BP was not explained by the greater use of antihypertensive treatment among frail or prefrail older adults. Because low BP could be detrimental among frail older adults, these findings raise questions about hypertension management in this population and stress the need for additional evidence.

Our results are consistent with other studies having shown that a diagnosis of hypertension was more frequent in frail than in non-frail individuals (**Table 2**), but that measured mean BP was lower in frail compared to non-frail individuals (**Table 3**).⁹ For instance, in a

cohort study by Aprahamian et al. in 2018, the prevalence of hypertension among non-frail, pre-frail, and frail individuals was 52%, 73%, and 83%, respectively.²⁵ With regard to BP, in one recent cross-sectional study by Gijón-Conde et al. conducted among 1047 participants aged 60 years and over, mean systolic BP was significantly lower by 1.5 mmHg per additional frailty category as measured by the frailty phenotype.²⁶ Other studies have been conducted using the frailty index based on the deficit accumulation model.²⁷ In one of these studies using electronic health records from 1.4 million people in the United Kingdom⁹, frailty was associated with low BP. In two other studies using cohort data from Canada and Korea, frailty was associated with a U-shaped BP curve.^{27,28} Our study is based on high quality data on BP and frailty and is, to our knowledge, the largest population-based study, which investigated the relationship between the frailty phenotype and BP. Although the frailty index may have a better ability to discriminate health risk in individuals, the frailty phenotype has a better clinical appeal, as the 5 criteria can be measured in clinical practice and interventions targeted on these features are possible.²⁹ This proximity to clinical practice is important in the context of decision-making on hypertension management.

Our study has several limitations. First, our sample included a relatively small number of frail individuals (n=121; 3.3% of the total sample). Second, although we adjusted our regression models for age, sex, history of CVD, BMI, socio-economic characteristics, and antihypertensive medication use, there might be some residual confounding. A potential confounder could be diet for instance. Third, we rely on self-reported data to some extent, e.g., data on hypertension diagnosis and antihypertensive medication use, and this data is less reliable than physical measurements. It is possible that some patients reporting antihypertensive medication use were actually taking them for other reasons than hypertension (e.g., heart failure), leading to a potential overestimation of the proportion of hypertension in this population. Furthermore, we had no detailed information on the type of antihypertensive medication. The participants were asked whether they use antihypertensive medication, without other specifications. Last, our analytical sample may be subject to some selection bias. As shown in **Figure 1**, out of the 4731 participants initially recruited, 3157 were finally included in our analyses. Between recruitment and last data collection, 381 died and 569 left the study. From those who participated at the most recent data collection, 394 were excluded from the analytical sample due to missing data, mainly in BP measurements (**Table 1**). In most cases, these participants could not, or were not willing to, attend the physical examination. Since some frail older adults may have not participated, it is possible that the proportion of frail individuals in our sample is an underestimation of the true proportion in the source population of this age. For the same reason, the association between frailty and BP may be systematically different in these individuals, because withdrawing from the study may be associated with both frailty and low BP. Nevertheless, there was no major difference between participants with or without missing data (see **Table S3** in the supplementary digital content files).

An important strength of our study is the high quality of data, especially regarding frailty and BP. The Lausanne cohort Lc65+ has been specifically designed to assess the development and determinants of frailty and, hence, frailty status has been carefully measured. Both BP and frailty have been measured for study purposes at the study center by trained study research assistants following a standardized procedure kept identical across years.¹⁶ BP has been measured three times at one visit, although not using home or ambulatory BP monitoring, but nonetheless in line with an ideal clinical setting, with participants in a resting state and sitting in a recommended posture.^{4,30} Another strength of

our study is that we used the frailty phenotype, and not the frailty index; the frailty phenotype, although less discriminative, is more appealing for clinical use.²⁹ In fine, the external validity of our findings may be challenged by selection bias and reduced representativeness, our results have a high internal validity due to reliable measurement methods for BP and frailty.

Our results suggest that an association between frailty and low BP exists, although the nature of this relationship stays unclear.¹ According to Hernán and Robins³¹, there are three structural reasons, why two variables may be associated: i.e. one variable is the cause of the other, both variables share a common cause, or the association was analyzed while conditioning on a common effect of both variables. **Figure 2** summarizes some hypotheses related to the previously mentioned reasons for an association. First, low BP may cause frailty (I). For instance, Muller et al. speculated that low BP causes frailty in older individuals because, in a physiologically vulnerable state, low BP may reduce blood perfusion and oxygenation of vital organs, and, hence, lead to damage, loss of functionality, and a state of frailty.³² Second, frailty may cause low BP (II). Indeed, a state of frailty is associated with a weakening of several physiological functions, including the ability of the heart to sustain a given level of BP. Third, frailty may cause low BP, which in turn could exacerbate frailty (III). Fourth, the relationship might be due to confounding (IV). For instance, poor nutrition or some debilitating diseases can cause both frailty and a low BP.⁹ The key is that confounding should be correctly assessed, using subject matter knowledge and integrating reflections on temporality, with some variables, for instance antihypertensive medications, acting as confounders at some time points and as mediators at some other time points. For these type of analyses, longitudinal data are needed, allowing the investigation of the effect of certain BP levels, but also of life long exposure to hypertension or to dynamic changes in BP as in end-of-life decline in BP.^{9,33} Finally, we cannot exclude the possibility that selection bias explains part of our findings. Further studies are needed to understand the possible mechanisms at play.

Currently, hypertension management in older adults is still highly debated. This is well illustrated by discordances across current major hypertension management guidelines. Recent North-American guidelines recommend treating older adults to systolic BP targets of 130 mmHg, irrespective of older age or frailty status.⁴ These recommendations have triggered criticism for downplaying and ignoring risks associated to low BP, such as falls, and physical and mental decline pinpointed in population-based cohort studies.^{10,34} More conservative, European guidelines published in 2018 emphasize that BP thresholds and BP treatment targets should be set accounting for biological age, and that frailty, independence, and tolerability of treatment have to be considered in the decision on how to treat a patient. According to the latter, older age, however, is not an argument for denying treatment per se. These guidelines recommend to lower systolic BP in older adults below 140 mmHg but not below 130 mmHg.⁵

Key in the debate is to understand the relationship between BP and frailty. In addition to being associated with low BP, frailty has been shown to be associated with a higher risk for orthostatic hypotension^{35,36} while the link with cardiovascular disease risk remains unclear.^{12,32,37} Since frail persons with multimorbidity and polypharmacy are highly prevalent and represent an ever-growing population in our ageing society, there is an urgent need to clarify this relationship to enable health care providers to adequately manage hypertension. While opinions diverge, with some authors speculating that lowering BP in frail patients is harmful and others who consider frailty as a risk factor for

undertreatment, there is a need for scientific evidence in frail participants.^{4,5,38} An analysis using longitudinal data and aiming for causal inference may help understanding the relationship between BP and frailty and give an indication on how to treat frail older adults for hypertension.

In conclusion, our results show that BP and frailty occur together in older adults, and raise the question on why they are related and on what is the impact of this relationship on the management of hypertension in older adults.

References

1. Anker D, Santos-Eggimann B, Santschi V, et al. Screening and treatment of hypertension in older adults: less is more? *Public health reviews*. 2018;39:26.
2. Benetos A, Rossignol P, Cherubini A, et al. Polypharmacy in the Aging Patient: Management of Hypertension in Octogenarians. *Jama*. 2015;314(2):170-180.
3. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. *The Cochrane database of systematic reviews*. 2009(4):Cd000028.
4. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension (Dallas, Tex : 1979)*. 2018;71(6):1269-1324.
5. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH 2018 ESC/ESH Guidelines for the management of arterial hypertension. *European heart journal*. 2018;39(33):3021-3104.
6. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. *The Cochrane database of systematic reviews*. 2018;4:Cd001841.
7. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. *The New England journal of medicine*. 2008;358(18):1887-1898.
8. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥ 75 Years: A Randomized Clinical Trial. *Jama*. 2016;315(24):2673-2682.
9. Ravindrarajah R, Hazra NC, Hamada S, et al. Systolic Blood Pressure Trajectory, Frailty, and All-Cause Mortality >80 Years of Age: Cohort Study Using Electronic Health Records. *Circulation*. 2017;135(24):2357-2368.
10. Sabayan B, Oleksik AM, Maier AB, et al. High blood pressure and resilience to physical and cognitive decline in the oldest old: the Leiden 85-plus Study. *Journal of the American Geriatrics Society*. 2012;60(11):2014-2019.
11. Streit S, Poortvliet RKE, Gussekloo J. Lower blood pressure during antihypertensive treatment is associated with higher all-cause mortality and accelerated cognitive decline in the oldest-old-data from the Leiden 85-plus Study. *Age and ageing*. 2018.
12. Odden MC, Peralta CA, Haan MN, Covinsky KE. Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. *Archives of internal medicine*. 2012;172(15):1162-1168.
13. van Hateren KJ, Hendriks SH, Groenier KH, et al. Frailty and the relationship between blood pressure and mortality in elderly patients with type 2 diabetes (Zwolle Outpatient Diabetes project Integrating Available Care-34). *Journal of hypertension*. 2015;33(6):1162-1166.
14. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet (London, England)*. 2013;381(9868):752-762.
15. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2004;59(3):255-263.
16. Santos-Eggimann B, Karmaniola A, Seematter-Bagnoud L, et al. The Lausanne cohort Lc65+: a population-based prospective study of the manifestations, determinants and outcomes of frailty. *BMC geriatrics*. 2008;8:20.

17. Macklai NS, Spagnoli J, Junod J, Santos-Eggimann B. Prospective association of the SHARE-operationalized frailty phenotype with adverse health outcomes: evidence from 60+ community-dwelling Europeans living in 11 countries. *BMC geriatrics*. 2013;13:3.
18. The Lc65+ cohort. [Internet]. Available from <https://lc65plus.iumsp.ch/>. Accessed 08.04.2019.
19. El Assaad MA, Topouchian JA, Darne BM, Asmar RG. Validation of the Omron HEM-907 device for blood pressure measurement. *Blood pressure monitoring*. 2002;7(4):237-241.
20. White WB, Anwar YA. Evaluation of the overall efficacy of the Omron office digital blood pressure HEM-907 monitor in adults. *Blood pressure monitoring*. 2001;6(2):107-110.
21. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2001;56(3):M146-156.
22. Mathiowetz V, Vizenor L, Melander D. Comparison of Baseline Instruments to the Jamar Dynamometer and the B&L Engineering Pinch Gauge. *OTJR Occupation Participation Health* 2000;20(3):147-162.
23. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychological function *Jama*. 1963;185:914-919.
24. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *The Gerontologist*. 1969;9(3):179-186.
25. Aprahamian I, Sasaki E, Dos Santos MF, et al. Hypertension and frailty in older adults. *Journal of clinical hypertension (Greenwich, Conn)*. 2018;20(1):186-192.
26. Gijon-Conde T, Graciani A, Lopez-Garcia E, et al. Frailty, Disability, and Ambulatory Blood Pressure in Older Adults. *Journal of the American Medical Directors Association*. 2018;19(5):433-438.
27. Rockwood K, Mitnitski A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. *Clin Geriatr Med*. 2011;27(1):17-26.
28. Kang MG, Kim SW, Yoon SJ, Choi JY, Kim KI, Kim CH. Association between Frailty and Hypertension Prevalence, Treatment, and Control in the Elderly Korean Population. *Sci Rep*. 2017;7(1):7542.
29. Kim DH, Schneeweiss S. Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations. *Pharmacoepidemiology and drug safety*. 2014;23(9):891-901.
30. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *European heart journal*. 2018;39(33):3021-3104.
31. Hernán MA, Robins JM. *Causal Inference*. Boca Raton: Chapman & Hall/CRC; 2019, forthcoming.
32. Muller M, Smulders YM, de Leeuw PW, Stehouwer CD. Treatment of hypertension in the oldest old: a critical role for frailty? *Hypertension (Dallas, Tex : 1979)*. 2014;63(3):433-441.
33. Delgado J, Bowman K, Ble A, et al. Blood Pressure Trajectories in the 20 Years Before Death. *JAMA Intern Med*. 2018;178(1):93-99.
34. Husten L. Search Results for: SPRINT [Internet] CardioBrief. 2017. Available from <http://www.cardiobrief.org/?s=SPRINT> Accessed 08.04.2019.

35. Rockwood MR, Howlett SE, Rockwood K. Orthostatic hypotension (OH) and mortality in relation to age, blood pressure and frailty. *Arch Gerontol Geriatr.* 2012;54(3):e255-260.
36. O'Connell MD, Savva GM, Fan CW, Kenny RA. Orthostatic hypotension, orthostatic intolerance and frailty: The Irish Longitudinal Study on Aging-TILDA. *Arch Gerontol Geriatr.* 2015;60(3):507-513.
37. Newman AB, Gottdiener JS, McBurnie MA, et al. Associations of subclinical cardiovascular disease with frailty. *The journals of gerontology Series A, Biological sciences and medical sciences.* 2001;56(3):M158-166.
38. Joyce E. Frailty and cardiovascular disease: A two-way street? *Cleveland Clinic journal of medicine.* 2018;85(1):65-68.
39. The Lc65+ cohort. Sampling. [Internet]. Available from <https://lc65plus.iumsp.ch/en/content/sampling>. Accessed 08.04.2019.

Funding:

None.

The Lc65+ study has been supported by University of Lausanne Hospital Centre; University of Lausanne Department of Ambulatory Care and Community Medicine; Canton de Vaud Department of Public Health; City of Lausanne; Loterie Romande [research grants 2006-2008 and 2018-2019]; Lausanne University Faculty of Biology and Medicine [multidisciplinary research grant 2006]; Swiss National Foundation for Scientific Research [grant 3247B0-120795/1]; and Fondation Médecine Sociale et Préventive, Lausanne. The sponsors had no role in the design, execution, analysis and interpretation of data, or writing of the study.

Conflict of interest:

The authors report no conflict of interest.

Acknowledgments:

Not Applicable.

Table 1. Baseline characteristics of participants at most recent data collection in the Lausanne cohort Lc65+.

Characteristics of participants		n (%)
Total N		3651
Sex	Women	2157 (59.1)
	Men	1494 (40.9)
	Missing	0 (0.0)
Age [years], mean (SD)		73.3 (4.1)
	Missing, n(%)	0 (0.0)
Socioeconomic characteristics	Living alone	2364 (64.8)
	Swiss citizenship	3223 (88.3)
	Education	
	Basic compulsory	645 (17.7)
	Apprenticeship	1410 (38.6)
	High school	902 (24.7)
	University	675 (18.5)
	Financial difficulties	938 (25.7)
	Missing in at least one variable in socioeconomic characteristics	419 (11.5)
	Frailty status	Non-frail
Pre-frail		1243 (34.1)
Frail		121 (3.3)
Missing		61 (1.7)
BP [mmHg], mean (SD)	Systolic BP	135.1 (18.5)
	Diastolic BP	76.3 (11.0)
	Missing, n(%)	441 (12.1)
Hypertension	Hypertension treatment or diagnosis (self-reported)	1867 (51.1)
	Missing	37 (1.0)
	Hypertension treatment (self-reported)	1601 (43.9)
	Missing	51 (1.4)
	BP \geq 140/90 mmHg (measured)	1248 (34.2)
	Missing	441 (12.1)
	BP \geq 140/90 mmHg (measured) or antihypertensive medication use (self-reported)	2243 (61.4)
Missing	248 (6.8)	
Other CVD risk factors	Hypercholesterolemia	1298 (35.6)
	Diabetes	417 (11.4)
	History of CVD	945 (25.9)
	Smoking	
	Current smoker	604 (16.5)
	Former smoker	1468 (40.2)
	Never smoker	1553 (42.5)
Missing in at least one variable in other CVD risk factors	79 (2.2)	
BMI [kg/m²], mean (SD)		26.9 (4.8)

	Missing, n(%)	442 (12.1)
BMI category	Underweight (BMI < 18.5 kg/m ²)	48 (1.3)
	Normal (BMI 18.5-24.9 kg/m ²)	1144 (31.3)
	Overweight (BMI 25-29.9 kg/m ²)	1305 (35.7)
	Obese (BMI ≥ 30 kg/m ²)	712 (19.5)
	Missing	442 (12.1)
Number of chronic diseases	0	746 (20.4)
	1	1092 (29.9)
	≥ 2	1813 (49.7)
Functional status	Help received with BADLs	
	No difficulties	2920 (80.0)
	Difficulties	375 (10.3)
	Difficulties and receiving help	113 (3.1)
	Missing	243 (6.7)
	Help received with IADLs	
	No difficulties	2773 (76.0)
	Difficulties	321 (8.8)
	Difficulties and receiving help	373 (10.2)
	Missing	184 (5.0)
Polypharmacy		751 (20.6)
	Missing	435 (11.9)

Values are numbers (%) unless indicated otherwise. n, number of participants; SD, standard deviation; BP, blood pressure; CVD, cardiovascular disease; BADL, basic activities of daily living; IADL, instrumental activities of daily living; Polypharmacy: self-reported use of ≥ 5 medication at least once a week.

Table 2. Number (%) of participants with hypertension, and using antihypertensive medication, stratified by sex, age and frailty status.

		Men (n=1299)				Women (n=1858)				Men and women
		67-70 years	71-75 years	76-80 years	All age categories	67-70 years	71-75 years	76-80 years	All age categories	All age categories
Diagnosed with or treated for hypertension	non-frail	164 (50.1)	118 (51.5)	165 (56.5)	447 (52.7)	134 (32.5)	124 (38.5)	179 (46.9)	437 (39.2)	884 (45.0)
	pre-frail	81 (66.4)	79 (62.7)	112 (66.7)	272 (65.4)	86 (49.1)	93 (52.0)	191 (60.4)	370 (55.2)	642 (59.1)
	frail	7 (70.0)	5 (83.3)	18 (94.7)	30 (85.7)	12 (70.6)	11 (52.4)	20 (58.8)	43 (59.7)	73 (68.2)
Treated for hypertension	non-frail	137 (41.9)	104 (45.4)	150 (51.4)	391 (46.1)	110 (26.7)	106 (32.9)	162 (42.4)	378 (33.9)	769 (39.2)
	pre-frail	71 (58.2)	71 (56.3)	99 (58.9)	241 (57.9)	68 (38.9)	79 (44.1)	172 (54.4)	319 (47.6)	560 (51.6)
	frail	6 (60.0)	4 (66.7)	15 (79.0)	25 (71.4)	11 (64.7)	7 (33.3)	13 (38.2)	31 (43.1)	56 (52.3)

The analytical sample consisted of 3157 participants with complete data for all variables. n, number of participants.

Table 3. Mean (SD) systolic and diastolic BP, stratified by sex, age and frailty status.

		Men (n=1299)				Women (n=1858)				Men and women
		67-70 years	71-75 years	76-80 years	All age categories	67-70 years	71-75 years	76-80 years	All age categories	All age categories
Systolic BP [mmHg]	non-frail	139.1 (16.0)	138.9 (17.6)	140.2 (17.7)	139.4 (17.0)	131.2 (18.9)	133.0 (17.8)	137.4 (19.7)	133.9 (19.1)	136.3 (18.4)
	pre-frail	139.2 (19.3)	136.0 (15.6)	136.8 (18.3)	137.3 (17.9)	130.0 (19.3)	129.1 (16.5)	133.1 (18.1)	131.2 (18.1)	133.4 (18.2)
	frail	134.1 (18.3)	130.8 (18.7)	131.4 (23.8)	132.1 (21.0)	126.8 (22.5)	128.5 (12.9)	128.4 (16.6)	128.1 (17.0)	129.1 (18.5)
Diastolic BP [mmHg]	non-frail	80.4 (10.8)	77.7 (10.5)	76.5 (10.8)	78.3 (10.9)	77.4 (10.6)	75.8 (9.9)	76.1 (10.6)	76.5 (10.5)	77.3 (10.7)
	pre-frail	77.5 (11.1)	75.1 (9.8)	74.4 (11.1)	75.6 (10.8)	77.0 (12.0)	73.5 (10.5)	74.0 (11.0)	74.7 (11.2)	74.9 (11.1)
	frail	77.3 (10.8)	73.9 (16.7)	64.6 (13.0)	69.8 (14.0)	73.6 (14.6)	75.0 (12.6)	71.2 (10.9)	72.9 (12.3)	71.6 (12.8)

The analytical sample consisted of 3157 participants with complete data for all variables. n, number of participants; SD, standard deviation; BP, blood pressure.


Table 4. Linear regression models of frailty upon systolic blood pressure (BP), and of frailty upon diastolic BP.

	Model 1	Model 2	Model 3
	Difference in BP (95%CI) [mmHg]	Difference in BP (95%CI) [mmHg]	Difference in BP (95%CI) [mmHg]
Systolic BP			
Frailty status			
Non-frail	ref	ref	ref
Pre-frail	-2.7 (-4.1 to -1.4)	-2.6 (-3.9 to -1.2)	-2.8 (-4.2 to -1.5)
Frail	-6.7 (-10.3 to -3.2)	-6.1 (-9.6 to -2.5)	-6.2 (-9.8 to -2.7)
Age			
67-70 years	ref	ref	ref
71-75 years	0.1 (-1.5 to 1.7)	0.5 (-1.2 to 2.2)	0.4 (-1.3 to 2.0)
76-80 years	2.9 (1.4 to 4.4)	3.5 (1.8 to 5.2)	3.0 (1.3 to 4.7)
Sex			
Men	ref	ref	ref
Women	-5.7 (-7.0 to -4.4)	-6.8 (-8.2 to -5.4)	-6.6 (-8.0 to -5.2)
BMI category			
Underweight	-	2.2 (-3.1 to 7.4)	2.5 (-2.7 to 7.7)
Normal weight	-	ref	ref
Overweight	-	3.0 (1.5 to 4.4)	2.4 (0.9 to 3.9)
Obese	-	1.6 (-0.2 to 3.4)	0.5 (-1.3 to 2.3)
Antihypertensive treatment			
No	-	-	ref
Yes	-	-	4.4 (3.0 to 5.8)
Diastolic BP			
Frailty status			
Non-frail	ref	ref	ref
Pre-frail	-1.9 (-2.8 to -1.1)	-1.8 (-2.6 to -1.0)	-1.8 (-2.7 to -1.0)
Frail	-4.9 (-7.0 to -2.8)	-4.4 (-6.5 to -2.3)	-4.4 (-6.5 to -2.3)
Age			
67-70 years	ref	ref	ref
71-75 years	-2.3 (-3.2 to -1.3)	-1.7 (-2.7 to -0.7)	-1.8 (-2.8 to -0.8)
76-80 years	-2.7 (-3.6 to -1.8)	-1.7 (-2.7 to -0.7)	-1.8 (-2.8 to -0.8)
Sex			
Men	ref	ref	ref
Women	-1.3 (-2.1 to -0.5)	-2.0 (-2.9 to -1.2)	-2.0 (-2.8 to -1.2)
BMI category			
Underweight	-	0.4 (-2.7 to 3.4)	0.4 (-2.7 to 3.5)
Normal weight	-	ref	ref
Overweight	-	2.8 (1.9 to 3.7)	2.8 (1.9 to 3.6)
Obese	-	3.7 (2.6 to 4.7)	3.6 (2.5 to 4.7)
Antihypertensive treatment			
No	-	-	ref
Yes	-	-	0.3 (-0.5 to 1.1)

Coefficients are differences in mean blood pressure (BP) as compared to the reference category (ref). The analytical sample consisted of 3157 participants with complete data for all variables. Model 1: adjusted for age and sex. Model 2: Model 1 + adjusted for socio-


economic characteristics (education, Swiss citizenship, financial difficulties, living alone), CVD risk factors (hypercholesterolemia, diabetes, history of CVD, smoking), and body mass index (BMI); Model 3: Model 2 + adjusted for antihypertensive medication use. 95% CI, 95% confidence interval.

Figure 1. Flow chart of individuals targeted, invited, and finally included in our analyses.



C1, sample 1 with a recruitment having started in 2004; C2, sample 2 with a recruitment having started in 2009; C3, sample 3 with a recruitment having started in 2014; N, total number of participants in the Lc65+; n, number of individuals.³⁹

Figure 2. Potential causal relationships explaining the association between blood pressure (BP) and frailty (F).



C, confounding factor.

Table S1. Detailed information about data collection for each variable.

Variables	Time point of data collection	Data collection method	Data output
Sex	Baseline	Population register	Binary (male / female)
Age	Baseline	Population register and date of data collection	Continuous
Socioeconomic characteristics			
Living alone	Most recent data collection	Self-reported	Binary (yes / no)
Swiss citizenship	Baseline	Self-reported	Binary (yes / no)
Education	Baseline	Self-reported	Categorical (basic compulsory / apprenticeship, high school / university)
Financial difficulties	Most recent data collection	Self-reported	Binary (yes / no)
Frailty status			
	Most recent data collection	Derived from variables below	Categorical (non-frail / pre-frail / frail)
Weakness (grip strength)	Most recent data collection	Measured	Binary (yes / no) Low grip strength was defined according to CHS gender and body mass index specific cut-off value
Slowness (walking speed)	Most recent data collection	Measured (slowness was imputed based on judgement of study research assistant in some cases)	Binary (yes / no) Low walking speed was defined according to CHS gender and body mass index specific cut-off value
Feeling of exhaustion	Most recent data collection	Self-reported	Binary (yes / no) The participant responds “a lot” to “did you have feelings of generalized weakness, weariness, lack of energy in the last four weeks?”
Shrinking (unvoluntary weight loss)	Most recent data collection	Self-reported	Binary (yes / no) The participant reports any unintentional weight loss in prior year
Low activity (physical activity)	Most recent data collection	Self-reported	Binary (yes / no) The participant reports: less than 20 minutes of sport activity once a week and less than 30 cumulated minutes walk per day 3 times a week and avoidance of stairs climbing or light loads carrying in daily activities
Systolic and diastolic BP			
	Most recent data collection	Measured	Continuous
Hypertension treatment or diagnosis			
	Baseline	Self-reported	Binary (yes / no)
	Most recent data collection	Self-reported	Binary (yes / no)

Hypertension treatment	Most recent data collection	Self-reported	Binary (yes / no)
Other CVD risk factors			
Hypercholesterolemia	Most recent data collection	Self-reported	Binary (yes / no)
Diabetes	Most recent data collection	Self-reported	Binary (yes / no)
History of CVD	Baseline	Self-reported	Binary (yes / no)
	Most recent data collection	Self-reported	
Smoking	Most recent data collection	Self-reported	Categorical (current smoker / former smoker / never smoker)
BMI	Most recent data collection	Measured (Weight and height were imputed based on self-reports in some cases)	Continuous
Number of chronic diseases	Most recent data collection	Self-reported	Categorical (0 / 1 / ≥ 2)
Functional status (BADL and IADL)	Most recent data collection	Self-reported	Categorical (no difficulties / difficulties for at least one activity / difficulties for at least one activity + need for assistance)
Polypharmacy	Most recent data collection	Self-reported	Binary (yes/no)

Baseline information was collected in 2004/05, 2009/10, and 2014/15 for sample 1, 2, and 3, respectively. Most recent data collection was in 2014, 2016 and 2015 for sample 1, 2, and 3, respectively. BP, blood pressure; CVD, cardiovascular disease; BMI, body mass index; BADL, basic activity of daily living; IADL, instrumental activity of daily living; CHS, Cardiovascular Health Study.

Table S2. Detailed overview for each sample of number of participants (%) at recruitment, at most recent data collection and included in our analytical sample (C1, C2, and C3) with number and reasons for dropouts and exclusions.

		C1		C2		C3		Total			
		N	%	N	%	N	%	N	% related to participants at recruitment	% related to participants at most recent data collection	
Number of participants at recruitment	Total	1564	100%	1489	100%	1678	100%	4731	100%		
	Permanent drop-outs from the study	Deceased	234	15%	133	9%	14	1%	381	8%	
		Quit study	248	16%	206	14%	115	7%	569	12%	
		Other	28	2%	33	2%	69	4%	130	3%	
Number of participants at most recent data collection	Total	1054	67%	1117	75%	1480	88%	3651	77%	100,0%	
	Reasons for missing data at most recent data collection	Only questionnaire	116		127		151		394		10,8%
		Only physical examination	3		2		1		6		0,2%
		Partial examination	2		1		3		6		0,2%
		Proxy	25		12		1		38		1,0%
		Missings for individual variables	27		10		13		50		1,4%
Participants with complete data for all variables included in regression models	Total	881	56%	965	65%	1311	78%	3157	67%	86,5%	

C1, sample 1; C2, sample 2; C3, sample 3

Table S3. Differences in main baseline characteristics between participants with complete data for all variables and participants with missing data at most recent data collection in the Lausanne cohort Lc65+.

Characteristics of participants		Analytical sample	Excluded from the analytical sample
N		3157	494
Sex	Women	1858 (58,9%)	299 (60,5%)
	Men	1299 (41,1%)	195 (39,5%)
	Missing		0
Age [years], mean (SD)		73,2 (4,0)	74,0 (4,0)
	Missing		0
Frailty status	Non-frail	1964 (62,2%)	262 (60,5%)
	Pre-frail	1086 (34,4%)	157 (36,3%)
	Frail	107 (3,4%)	14 (3,2%)
	Missing		61
BP [mmHg], mean (SD)	Systolic BP	135,1 (18,4)	133,4 (21,9)
	Diastolic BP	76,3 (11,0)	74,7 (13,1)
	Missing		441
Hypertension treatment or diagnosis		1599 (50,6%)	268 (58,6%)
	Missing		37
Hypertension treatment		1385 (43,9%)	216 (48,8%)
	Missing		51

Values are numbers (%) unless indicated otherwise. n, number of participants; SD, standard deviation; BP, blood pressure.